is an investment and financial services company specialising in Investment Banking, Corporate Advisory and Share Trading services for Australian corporate and private clients, and overseas corporate clients.

  • Address: Level 24, Royal Exchange Building, 56 Pitt Street, Sydney, NSW 2000 Australia
  • Phone: +61 2 9375 0100
  • Email: Contact Us
Koligo Therapeutics Ltd

Koligo Therapeutics Ltd

Koligo Therapeutics Limited (the Company) was incorporated on 27 June 2018 for the primary purpose of acquiring Koligo Therapeutics, Inc. (a company incorporated in the Commonwealth of Kentucky in the United States) (Koligo).

Koligo is a U.S.-based biotechnology company focused on the development and commercialisation of a range of cell therapy, three-dimensional (3D) bioprinted tissue and other regenerative medicine products for serious unmet medical needs.

Koligo has successfully commercialised and has recently commenced selling its first cell therapy transplant product, Kyslecel™, in the United States. Kyslecel™ is used in the treatment of patients suffering from chronic or acute recurrent pancreatitis, a debilitating and painful condition with few effective treatment options. Koligo is currently developing Kyslecel™ v2.0, an improved formulation that is intended to extend its shelf life and thus expand the markets it serves.

The Offer

For an offer of 30,000,000 Shares at an issue price of $0.20 per Share to raise $6,000,000 (Public Offer). Oversubscriptions of up to a further 5,000,000 Shares at an issue price of $0.20 per Share to raise up to a further $1,000,000 may be accepted under the Public Offer, and for the offer of up to 5,500,000 Options to the Joint Lead Managers

For further information, please contact Campbell Welch of Novus Capital Limited on 02 9375 0165 or via email campbell.welch@novuscapital.com.au